Published in J Nucl Cardiol on December 01, 2012
Histological Validation Of Carotid Plaque Composition In Preoperative Imaging | NCT01456403
Natural history of atherosclerotic disease progression as assessed by (18)F-FDG PET/CT. Int J Cardiovasc Imaging (2015) 0.88
Haemodynamical stress in mouse aortic arch with atherosclerotic plaques: Preliminary study of plaque progression. Comput Struct Biotechnol J (2014) 0.83
Identification of inflamed atherosclerotic lesions in vivo using PET-CT. Inflammation (2014) 0.81
Recent advances in pathogenesis, assessment, and treatment of atherosclerosis. F1000Res (2016) 0.77
Molecular magnetic resonance imaging of atherosclerotic vessel wall disease. Eur Radiol (2015) 0.76
Carotid Artery FDG Uptake May Serve as a Biomarker for Cardiovascular Risk Stratification in Asymptomatic Adults. Nucl Med Mol Imaging (2014) 0.76
Imaging VEGF receptor expression to identify accelerated atherosclerosis. EJNMMI Res (2014) 0.75
Imaging Subclinical Atherosclerosis: Where Do We Stand? Curr Cardiol Rev (2017) 0.75
Aortic ¹⁸F-FDG uptake in patients suffering from granulomatosis with polyangiitis. Eur J Nucl Med Mol Imaging (2015) 0.75
Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet (1997) 44.03
Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract (2009) 25.83
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00
Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) (2008) 9.45
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med (2003) 5.43
Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis (1986) 5.23
Atherosclerosis is an inflammatory disease. Am Heart J (1999) 5.12
Atherosclerosis: current pathogenesis and therapeutic options. Nat Med (2011) 4.95
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med (2008) 4.54
Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation (2002) 4.43
Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol (2005) 4.29
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol (2006) 3.91
The respiratory burst of phagocytes. J Clin Invest (1984) 3.86
In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation (2001) 3.47
Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol (2010) 3.45
Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol (2006) 3.43
Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler Thromb Vasc Biol (2004) 3.37
Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol (2006) 3.36
Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation (1996) 3.34
Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med (1992) 3.31
Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation (2001) 3.12
Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol (2007) 2.97
Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol (2009) 2.80
In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation (2005) 2.76
Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation (2004) 2.72
Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol (2002) 2.53
Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med (2008) 2.52
Neovascularization in human atherosclerosis. Circulation (2006) 2.44
Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation (2000) 2.38
Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging (2010) 2.38
(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol (2007) 2.32
Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med (2009) 2.21
Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation (2011) 2.21
18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med (2009) 2.19
Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke (2002) 2.10
Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology (1982) 1.99
Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol (2006) 1.89
Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J (2011) 1.82
The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging (2011) 1.80
Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol (2006) 1.79
Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc (2004) 1.77
Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Circulation (1998) 1.74
Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009) 1.66
SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med (2010) 1.63
Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques. JACC Cardiovasc Imaging (2011) 1.63
Molecular and cellular imaging of atherosclerosis: emerging applications. J Am Coll Cardiol (2006) 1.59
Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun (2010) 1.57
Contrast-enhanced ultrasound imaging of intraplaque neovascularization in carotid arteries: correlation with histology and plaque echogenicity. J Am Coll Cardiol (2008) 1.53
Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol (2007) 1.53
Changing patterns of abnormal vascular wall F-18 fluorodeoxyglucose uptake on follow-up PET/CT studies. J Nucl Cardiol (2006) 1.51
Rates of utilization and fates of glucose, glutamine, pyruvate, fatty acids and ketone bodies by mouse macrophages. Biochem J (1987) 1.45
Assessment of inactive, active and mixed atherosclerotic plaques by 18F-FDG-PET; an age group-based correlation with cardiovascular risk factors. Int J Cardiovasc Imaging (2008) 1.45
Uptake of F-18 FDG and ultrasound analysis of carotid plaque. J Nucl Cardiol (2011) 1.43
Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis (2009) 1.40
Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg (2008) 1.38
Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med (2004) 1.34
Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ Cardiovasc Imaging (2011) 1.33
Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography, 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation (1983) 1.32
Vasa vasorum and plaque neovascularization on contrast-enhanced carotid ultrasound imaging correlates with cardiovascular disease and past cardiovascular events. Stroke (2009) 1.29
F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med (2001) 1.28
Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology (2003) 1.28
The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease--study design and objectives. Am Heart J (2010) 1.27
Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med (2005) 1.26
Radionuclide imaging for the detection of inflammation in vulnerable plaques. J Am Coll Cardiol (2006) 1.25
What is the natural history of 18F-FDG uptake in arterial atheroma on PET/CT? Implications for imaging the vulnerable plaque. Atherosclerosis (2010) 1.22
Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med (2008) 1.18
Mechanical stress analysis of a rigid inclusion in distensible material: a model of atherosclerotic calcification and plaque vulnerability. Am J Physiol Heart Circ Physiol (2009) 1.18
3D ultrasound measurement of change in carotid plaque volume: a tool for rapid evaluation of new therapies. Stroke (2005) 1.17
Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography. Circ Cardiovasc Imaging (2010) 1.15
Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol (1991) 1.15
Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am J Cardiol (2002) 1.13
Differences in plaque composition and distribution in stable coronary artery disease versus acute coronary syndromes; non-invasive evaluation with multi-slice computed tomography. Acute Card Care (2007) 1.11
In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med (2010) 1.11
The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography. Eur Heart J (2007) 1.09
Correlation of inflammation assessed by 18F-FDG PET, active mineral deposition assessed by 18F-fluoride PET, and vascular calcification in atherosclerotic plaque: a dual-tracer PET/CT study. J Nucl Med (2011) 1.05
18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med (2002) 1.04
Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med (2010) 1.03
Association of inflammation of the left anterior descending coronary artery with cardiovascular risk factors, plaque burden and pericardial fat volume: a PET/CT study. Eur J Nucl Med Mol Imaging (2010) 1.02
In vivo imaging of mineral deposition in carotid plaque using 18F-sodium fluoride PET/CT: correlation with atherogenic risk factors. J Nucl Med (2011) 1.02
What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro. J Nucl Med (2011) 1.02
Imaging biomarkers in atherosclerosis trials. Circ Cardiovasc Imaging (2011) 1.02
High-resolution imaging of human atherosclerotic carotid plaques with micro 18F-FDG PET scanning exploring plaque vulnerability. J Nucl Cardiol (2011) 1.01
Increased peripheral benzodiazepine receptors in arterial plaque of patients with atherosclerosis: an autoradiographic study with [(3)H]PK 11195. Atherosclerosis (2008) 1.00
Investigating vulnerable atheroma using combined (18)F-FDG PET/CT angiography of carotid plaque with immunohistochemical validation. J Nucl Med (2011) 0.98
Quantitative assessment of the atherosclerotic burden of the aorta by combined FDG-PET and CT image analysis: a new concept. Nucl Med Biol (2006) 0.98
Investigation of [18F]2-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism. J Nucl Med (1978) 0.96
Carotid plaque inflammation is associated with cerebral microembolism in patients with recent transient ischemic attack or stroke: a pilot study. Circ Cardiovasc Imaging (2010) 0.96
PET and SPECT imaging of apoptosis in vulnerable atherosclerotic plaques with radiolabeled Annexin A5. Q J Nucl Med Mol Imaging (2009) 0.93
Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur J Nucl Med Mol Imaging (2009) 0.92
Characterization of carotid artery plaques with USPIO-enhanced MRI: assessment of inflammation and vascularity as in vivo imaging biomarkers for plaque vulnerability. Int J Cardiovasc Imaging (2010) 0.91
Arterial foci of F-18 fluorodeoxyglucose are associated with an enhanced risk of subsequent ischemic stroke in cancer patients: a case-control pilot study. Clin Nucl Med (2011) 0.91
Detection and quantification of large-vessel inflammation with 11C-(R)-PK11195 PET/CT. J Nucl Med (2010) 0.90
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med (2014) 6.73
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14
Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J (2005) 4.06
Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA (2010) 4.05
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation (2010) 3.72
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation (2011) 3.01
Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol (2012) 2.94
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke (2007) 2.63
Patient management after noninvasive cardiac imaging results from SPARC (Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease). J Am Coll Cardiol (2012) 2.60
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation (2010) 2.51
Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol (2011) 2.51
Symptomatic myocardial bridges: overview of ischemic mechanisms and current diagnostic and treatment strategies. J Am Coll Cardiol (2003) 2.48
Atrial fibrillation promotion by endurance exercise: demonstration and mechanistic exploration in an animal model. J Am Coll Cardiol (2013) 2.38
Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet (2013) 2.37
Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2012) 2.34
Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation (2008) 2.34
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J (2012) 2.30
Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol (2008) 2.29
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J (2009) 2.21
Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation (2003) 2.16
Long-term safety of intravascular ultrasound in nontransplant, nonintervened, atherosclerotic coronary arteries. J Am Coll Cardiol (2005) 2.14
Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. Am J Physiol Heart Circ Physiol (2002) 2.00
Does quantification of myocardial flow reserve using rubidium-82 positron emission tomography facilitate detection of multivessel coronary artery disease? J Nucl Cardiol (2012) 1.90
Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation (2007) 1.88
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J (2014) 1.88
MicroRNA-133 controls brown adipose determination in skeletal muscle satellite cells by targeting Prdm16. Cell Metab (2013) 1.87
Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging (2007) 1.85
Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation (2003) 1.83
Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation (2012) 1.81
Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. Genes Dev (2006) 1.80
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72
Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol (2004) 1.72
Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation (2003) 1.69
Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation (2004) 1.64
Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging (2009) 1.63
Absence of association between infectious agents and endothelial function in healthy young men. Circulation (2003) 1.60
Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea. Heart Rhythm (2012) 1.59
State-of-the-art imaging of acute stroke. Radiographics (2006) 1.59
18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med (2010) 1.56
Motor vehicle accidents: the most common cause of traumatic vertebrobasilar ischemia. Can J Neurol Sci (2003) 1.56
Geometry of the carotid bifurcation predicts its exposure to disturbed flow. Stroke (2008) 1.54
The effects of continuous positive airway pressure on myocardial energetics in patients with heart failure and obstructive sleep apnea. J Am Coll Cardiol (2007) 1.53
The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med (2012) 1.52
What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol (2006) 1.52
Atrial fibrillation-associated remodeling does not promote atrial thrombus formation in canine models. Circ Arrhythm Electrophysiol (2012) 1.50
Effects of anesthetic induction in patients with diastolic dysfunction. Can J Anaesth (2009) 1.50
Influence of noninvasive cardiovascular imaging in primary prevention: systematic review and meta-analysis of randomized trials. Arch Intern Med (2011) 1.50
Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. Circ Heart Fail (2012) 1.48
Complications of Type 2 Diabetes Among Aboriginal Canadians: prevalence and associated risk factors. Diabetes Care (2005) 1.46
Single low-dose CT scan optimized for rest-stress PET attenuation correction and quantification of coronary artery calcium. J Nucl Cardiol (2014) 1.46
Prognostic significance of impaired chronotropic response to pharmacologic stress Rb-82 PET. J Nucl Cardiol (2014) 1.46
Role of T-type calcium channel subunits in post-myocardial infarction remodelling probed with genetically engineered mice. Cardiovasc Res (2011) 1.44
Accuracy of low-dose rubidium-82 myocardial perfusion imaging for detection of coronary artery disease using 3D PET and normal database interpretation. J Nucl Cardiol (2012) 1.44
Two-year angiographic follow-up of intracoronary Sr90 therapy for restenosis prevention after balloon angioplasty. Circulation (2002) 1.42
Quantitative assessment of carotid plaque composition using multicontrast MRI and registered histology. Magn Reson Med (2003) 1.41
Diabetes, intracranial stenosis and microemboli in asymptomatic carotid stenosis. Can J Neurol Sci (2013) 1.41
Incidence of stent under-deployment as a cause of in-stent restenosis in long stents. Int J Cardiovasc Imaging (2004) 1.41
Enlargement of catheter ablation lesions in infant hearts with cryothermal versus radiofrequency energy: an animal study. Circ Arrhythm Electrophysiol (2011) 1.40
Effect of intravenous nitroglycerin on cerebral saturation in high-risk cardiac surgery. Can J Anaesth (2007) 1.39
Reconstruction of carotid bifurcation hemodynamics and wall thickness using computational fluid dynamics and MRI. Magn Reson Med (2002) 1.38
Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in European ancestry individuals. PLoS Genet (2011) 1.38
Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times (ESCAPE) trial: methodology. Int J Stroke (2014) 1.38
Does FDG PET-assisted management of patients with left ventricular dysfunction improve quality of life? A substudy of the PARR-2 trial. Can J Cardiol (2011) 1.37
In vivo validation of a catheter-based near-infrared spectroscopy system for detection of lipid core coronary plaques: initial results of the SPECTACL study. JACC Cardiovasc Imaging (2009) 1.37
Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. EuroIntervention (2011) 1.35
Vitamin B12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products. CMAJ (2005) 1.34
Extremes of unexplained variation as a phenotype: an efficient approach for genome-wide association studies of cardiovascular disease. Circ Cardiovasc Genet (2010) 1.33
Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation (2002) 1.31
Relation between conduit vessel stiffness (assessed by tonometry) and endothelial function (assessed by flow-mediated dilatation) in patients with and without coronary heart disease. Am J Cardiol (2003) 1.29
Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension (2007) 1.29
Dietary intervention to reverse carotid atherosclerosis. Circulation (2010) 1.28
New and emerging weight management strategies for busy ambulatory settings: a scientific statement from the American Heart Association endorsed by the Society of Behavioral Medicine. Circulation (2011) 1.27
Variation in the carotid bifurcation geometry of young versus older adults: implications for geometric risk of atherosclerosis. Stroke (2005) 1.27
Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart (2011) 1.26
Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke (2004) 1.26
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol (2011) 1.24
Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. J Am Coll Cardiol (2007) 1.23
Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol (2007) 1.22
Measurement of carotid plaque volume by 3-dimensional ultrasound. Stroke (2004) 1.21
Sex differences in carotid plaque and stenosis. Stroke (2004) 1.20
Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol (2012) 1.20
Role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension (2007) 1.19
Quantitative analysis of coronary endothelial function with generator-produced 82Rb PET: comparison with 15O-labelled water PET. Eur J Nucl Med Mol Imaging (2010) 1.17